Loncastuximab Tesirine-lpyl Injection Uses, Dosage, Side Effects and Interactions
Zynlonta
Zynlonta is a brand of loncastuximab tesirine-lpyl injection that comes as an injection.
Loncastuximab tesirine-lpyl (Zynlonta) is an intravenous cancer medicine used for adults whose large B-cell lymphoma has come back or has not responded after two or more earlier treatments.
Quick links
Ask Anything About Loncastuximab Tesirine-lpyl InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Loncastuximab Tesirine-lpyl Injection in Short
What it treatsZynlonta is used for adults with relapsed or refractory large B-cell lymphoma. This means the cancer came back or did not respond after two or more earlier systemic (whole-body) treatments.
- How you get it Prescription only
- Comes asInjection (into a vein)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- Supplements and herbs38 interact 1 major, 29 moderate and 8 minor
The Pharmacist’s Take
Zynlonta is a later-line drug for adults whose large B-cell lymphoma came back or stopped responding after two or more treatments. It is an antibody that latches onto CD19 on B cells and carries a DNA-damaging drug inside them, on the market since 2021 and not available as a generic. For a lymphoma treatment it is fairly manageable, and what people notice most is tiredness, swelling, nausea and rash or sun sensitivity. The thing to watch is fluid buildup, so report new swelling, rapid weight gain or shortness of breath promptly, and treat any fever as urgent because low blood counts make infections dangerous. Your team will check blood counts and liver tests throughout.
Key Takeaways From the HelloPharmacist Team
- Expect a 30-minute IV infusion at the clinic every 3 weeks, with a lower dose after the first two cycles.
- Take the steroid dexamethasone for 3 days, starting the day before each infusion, unless your doctor tells you otherwise.
- Cover up and use sunscreen outdoors, and avoid sun even through windows, since Zynlonta can cause sunburn-like skin reactions.
- If pregnancy is possible, use effective birth control during treatment and for 10 months after for women, or 7 months for men.
Patient Information Guide for Loncastuximab Tesirine-lpyl Injection
What It’s Used For
Loncastuximab tesirine-lpyl is used to treat a type of lymphoma in adults.
- ZYNLONTA (intravenous) treats relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
- This includes DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
- It was approved under accelerated approval based on response rate, and continued approval may depend on confirmatory trials.
How It Works
Loncastuximab tesirine-lpyl is an antibody-drug conjugate. The antibody portion binds to CD19, a protein on B cells. Once attached, the drug is taken into the cell and releases SG3199, which damages DNA and causes cell death. It showed anticancer activity in animal models of lymphoma.
Drug Class
WHO drug family
- Other monoclonal antibodies and antibody drug conjugates
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)None. The FDA’s index lists no class of any kind for Loncastuximab Tesirine-lpyl Injection.
The main drug class the FDA gives it. It is the class named on the drug’s label.
What It Does in the Body
Physiologic effect (PE)None listed for Loncastuximab Tesirine-lpyl Injection in the FDA’s index.
From our Patient Information GuideLoncastuximab tesirine-lpyl is an antibody-drug conjugate. The antibody portion binds to CD19, a protein on B cells. Once attached, the drug is taken into the cell and releases SG3199, which damages DNA and causes cell death. Read How Loncastuximab Tesirine-lpyl Injection Works
A change it makes in how the body works.
Drug Family
WHO ATC classification- Other monoclonal antibodies and antibody drug conjugates
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification, from the U.S. National Library of Medicine’s RxClass. Reference only, not medical advice.
Dosage
ZYNLONTA is given by a healthcare professional as a 30-minute infusion into a vein, on Day 1 of each 3-week cycle. The dose is higher for the first two cycles and lower afterward.
- A steroid (dexamethasone) is taken for 3 days, starting the day before each infusion, unless it is not appropriate.
- Treatment may be delayed or the dose reduced if side effects occur.
- Your care team will tell you what to do if an appointment is missed.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Large B-cell lymphoma that came back or did not respond to treatment
Adults · Cycles 1 and 2 Starting dose 0.15 mg/kg every 3 weeks
- 0.15 mg/kg every 3 weeks for 2 cycles, as an intravenous infusion over 30 minutes on Day 1 of each cycle
Adults · Later cycles Usual dose 0.075 mg/kg every 3 weeks
- 0.075 mg/kg every 3 weeks for subsequent cycles, as an intravenous infusion over 30 minutes on Day 1 of each cycle
Good to know
For patients with BMI ≥35 kg/m2, dose is calculated on adjusted body weight
BMI stands for body mass index.
Adults · Premedication Usual dose 4 mg of dexamethasone twice a day
- Dexamethasone 4 mg orally or intravenously twice daily for 3 days beginning the day before Zynlonta
Good to know
If not begun the day before, start dexamethasone at least 2 hours before Zynlonta
Side Effects
The most common side effects, including lab changes, are:
Common side effects
- Low platelets, neutrophils or red blood cells
- Raised liver tests (GGT, AST, ALT)
- Tiredness
- Rash, itching or sun sensitivity
- Swelling (edema)
- Nausea
- Muscle or bone pain
- High blood sugar
- High blood sugar and low albumin
When to get medical help
- Call your care team if you have new or worse shortness of breath, chest pain, or swelling in your belly or bloating. These can signal fluid around the lungs or heart.
- Report new or worsening swelling, rapid weight gain or severe dizziness. These can be signs of fluid buildup or capillary leak syndrome.
- Seek help right away for fever, chills or other signs of infection. Serious and fatal infections have occurred.
- Tell your doctor about a new or worsening skin rash, blisters or sunburn-like reactions.
- Report signs of liver problems, as severe liver injury has occurred. Your doctor will check liver tests during treatment.
- Tell your care team if the IV site becomes painful, swollen or irritated during the infusion.
Warnings and Precautions
- Fluid buildup: effusions, edema and capillary leak syndrome can occur. Watch for shortness of breath, chest pain, belly swelling or weight gain.
- Low blood counts: neutropenia, thrombocytopenia and anemia can be severe. Blood counts are checked throughout treatment.
- Infections: serious and fatal infections have occurred.
- Liver injury: liver tests are monitored, and treatment may be paused or stopped.
- Skin reactions: avoid sun exposure and use protection.
- Pregnancy: it can cause fetal harm.
Before You Start
- Pregnancy: it can harm an unborn baby. Pregnancy testing is recommended before starting.
- Contraception: use it for 10 months after the last dose (females) or 7 months (males with female partners who could become pregnant).
- Breastfeeding: do not breastfeed during treatment and for 3 months afterward.
- Male fertility may be affected.
- Liver disease: avoid in severe impairment. Mild impairment needs closer monitoring.
- Children: safety and effectiveness have not been established.
- Older adults: no overall differences in safety or effectiveness were seen.
Half-Life and How Your Body Processes It
The antibody portion is expected to be broken down into small peptides. The cell-killing part (SG3199) is processed by the CYP3A4/5 enzymes in lab studies and is expected to be minimally cleared by the kidneys. The half-life is about 21 days at steady state, and steady state is reached after about 105 days. Age, sex, race, body weight and mild to moderate kidney impairment did not cause meaningful differences.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Loncastuximab Tesirine-lpyl Injection Drug Interactions
Supplements and Herbs That Interact With Loncastuximab Tesirine-lpyl Injection
From the licensed clinical database we use, rolled up per supplement, most serious first.38 supplements and herbal products have documented interactions with Loncastuximab Tesirine-lpyl Injection in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 1Major
- 29Moderate
- 8Minor
- ST. JOHN'S WORTMajor
- BITTER MELONModerate
- BLACK PEPPERModerate
- BULBINE NATALENSISModerate
- CANNABISModerate
- DANSHENModerate
- DELTA-9-TETRAHYDROCANNABINOL (THC)Moderate
- DIOSMINModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Loncastuximab Tesirine-lpyl Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Loncastuximab Tesirine-lpyl Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is Zynlonta used for?
How is Zynlonta given?
What side effects should I expect?
Do I need to avoid the sun on Zynlonta?
Can I take Zynlonta if I'm pregnant or breastfeeding?
How long does Zynlonta stay in my body?
Is loncastuximab tesirine-lpyl injection available over the counter?
When was loncastuximab tesirine-lpyl injection first available?
What is the brand name of loncastuximab tesirine-lpyl injection?
What is the generic name of Zynlonta?
What strengths does loncastuximab tesirine-lpyl injection come in?
Where can I read the loncastuximab tesirine-lpyl injection prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Loncastuximab Tesirine-lpyl Injection
Skip the scrolling. Ask in your own words and get an answer from Loncastuximab Tesirine-lpyl Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Loncastuximab Tesirine-lpyl Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Loncastuximab Tesirine-lpyl Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Loncastuximab Tesirine-lpyl Injection Forms and Strengths (How It Comes)
Loncastuximab Tesirine-lpyl Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Loncastuximab Tesirine-lpyl Injection inactive ingredients by manufacturer.
Injection
How this form is used
- ZYNLONTA is used for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
- ZYNLONTA is given as an intravenous infusion over 30 minutes.
- ZYNLONTA is given on Day 1 of each 3-week cycle.
- ZYNLONTA is prepared from a powder and diluted before infusion by trained staff.
- ZYNLONTA is preceded by dexamethasone for 3 days, starting the day before, unless it is not appropriate.
Loncastuximab Tesirine-lpyl Injection on the U.S. Market: Products, Makers and Brands
How Loncastuximab Tesirine-lpyl Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Loncastuximab Tesirine-lpyl Injection product record with the FDA, mostly as injection; the earliest marketing or approval year on record is 2021. The one brand name in the directory today is Zynlonta; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished injection, powder, lyophilized, for solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
How Widely Loncastuximab Tesirine-lpyl Injection Is Used (Medicaid Data)
How many Loncastuximab Tesirine-lpyl Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Loncastuximab Tesirine-lpyl Injection prescribed? Of the 1,682 medications we measure, Loncastuximab Tesirine-lpyl Injection ranks #1,644 by Medicaid prescriptions — more than 2% of them.
Utilization by Loncastuximab Tesirine-lpyl Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
loncastuximab tesirine-lpyl 10 MG Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 2540969
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 1 of the 1 listed Loncastuximab Tesirine-lpyl Injection NDCs had Medicaid claims.
Compare Loncastuximab Tesirine-lpyl Injection Products
A representative set of FDA-listed product records for Loncastuximab Tesirine-lpyl Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10 mg/2 mL | Intravenous | ADC Therapeutics America, Inc. | BLA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Loncastuximab Tesirine-lpyl Injection NDCs →
Loncastuximab Tesirine-lpyl Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Loncastuximab Tesirine-lpyl Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Loncastuximab Tesirine-lpyl Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Loncastuximab Tesirine-lpyl Injection FDA Approval History
How Loncastuximab Tesirine-lpyl Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Loncastuximab Tesirine-lpyl Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Loncastuximab Tesirine-lpyl recalls since July 2021.
✅No Loncastuximab Tesirine-lpyl recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Loncastuximab Tesirine-lpyl Injection in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 1
- Forms in current FDA listings
- 1 of 1
RxCUI 2540964 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 2540968Its strength (SCD)-
10 mg
lpyl
RxCUI 2540969
-
10 mg
lpyl
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Loncastuximab Tesirine-lpyl Injection Supply and Shortage Status
Whether Loncastuximab Tesirine-lpyl Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Loncastuximab Tesirine-lpyl Injection Brand Names
Loncastuximab Tesirine-lpyl Injection has one brand name on record: Zynlonta. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Loncastuximab Tesirine-lpyl Injection: Manufacturers and Labelers
One company lists Loncastuximab Tesirine-lpyl Injection products with the FDA. By number of product records, the largest are ADC Therapeutics America, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Loncastuximab Tesirine-lpyl Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. ADC Therapeutics America, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →